Please login to the form below

Not currently logged in
Email:
Password:

Takeda buys Nycomed and names CEO

Takeda has completed the purchase of Switzerland-based pharmaceutical firm Nycomed and named Dr Frank Morich as Nycomed's CEO

Takeda has completed the purchase of Switzerland-based pharmaceutical firm Nycomed for €9.6bn, making Nycomed a wholly owned subsidiary of Takeda.

Takeda also named current executive vice president of international operations (Americas/Europe) at Takeda, Dr Frank Morich, as CEO of the newly acquired company.

The deal fits Japan-based Takeda's plans for international growth, with Nycomed holding a strong presence in Europe as well as making recent investments in emerging markets such as Russia and China.

Yasuchika Hasegawa, president and CEO of Takeda, said: "Partnering the two organisations will have complementary effects and further increase our potential to become a truly global pharmaceutical company."

Commenting on his appointment, Morich was positive about the acquisition that will see Takeda's coverage of the global pharmaceutical market increase to more than 70 countries.

He said: "I look forward to bringing Takeda and Nycomed together to ensure we can achieve enhanced revenue, growth and diversification, while maintaining the strong momentum of both companies."

Takeda also named other executive changes at the company, including renaming the company's international operations (Asia) division to international operations (North Asia).

Haruhiko Hirate, former corporate officer, senior vice president, international operations (Asia) will take up the same position in the newly named North Asia division, while Shinji Honda, former chief integration officer at Takeda will become chief integration officer at Nycomed.

Trevor Smith, CEO at Takeda, will remain in his position as well as taking over the role of head of Europe and Canada commercial operations at Nycomed.

3rd October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health4Brands

At H4B, we are an energetic new team with fresh ideas, but we have over 275 years of combined experience...

Latest intelligence

Rise of generics will curb France’s pharma growth
Generics are set to take a serious bite out of the market as a cash-strapped government pushes for cost controls...
blog-icon_account_for_clm_final.png
How to account for different motivations in closed loop marketing
While your CLM technology might be brand new, the communications strategy behind should be tried and tested. In fact one of the earliest exponents of rhetoric, Aristotle, can still inform...
Framing, provocation, and truth
It all depends on how you ask the question…...

Infographics